New radio-hybrid approach combines PET and SPECT for more precisely targeted prostate cancer treatment

Prostate cancer is one of the most common cancers among men worldwide. However, in the case of advanced, metastatic tumours, there is often a lack of precise tools for planning individualised radiotherapy treatments. A research team led by Dr Constantin Mamat from the Institute for Radiopharmaceutical Cancer Research at the Helmholtz Centre Dresden-Rossendorf (HZDR) has now tested a novel diagnostic approach that combines two imaging techniques and could pave the way for highly personalised radiotherapy. The Wilhelm Sander Foundation funded the study with 166,000 euros. The results were published in the *Journal of Medicinal Chemistry*.